iRhythm Technologies, Inc.

LSE:0A7L Stock Report

Market Cap: US$4.5b

iRhythm Technologies Valuation

Is 0A7L undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A7L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$37.14
Fair Value
347.0% overvalued intrinsic discount
12
Number of Analysts

Below Fair Value: 0A7L ($166) is trading above our estimate of fair value ($37.14)

Significantly Below Fair Value: 0A7L is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A7L?

Key metric: As 0A7L is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0A7L. This is calculated by dividing 0A7L's market cap by their current revenue.
What is 0A7L's PS Ratio?
PS Ratio8.1x
SalesUS$657.23m
Market CapUS$4.50b

Price to Sales Ratio vs Peers

How does 0A7L's PS Ratio compare to its peers?

The above table shows the PS ratio for 0A7L vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.9x
SN. Smith & Nephew
2.3x5.02%UK£10.1b
NIOX NIOX Group
7x10.78%UK£292.3m
EKF EKF Diagnostics Holdings
2.8x6.83%UK£139.2m
OBI Ondine Biomedical
51.6xn/aUK£57.8m
0A7L iRhythm Technologies
8.1x14.42%US$4.5b

Price-To-Sales vs Peers: 0A7L is good value based on its Price-To-Sales Ratio (8.1x) compared to the peer average (15.9x).

Price to Sales Ratio vs Industry

How does 0A7L's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.2x2.37%US$55.96m
DEMG Deltex Medical Group
0.3xn/aUS$575.27k
No more companies available in this PS range
0A7L 8.1xIndustry Avg. 2.5xNo. of Companies4PS0246810+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0A7L is expensive based on its Price-To-Sales Ratio (8.1x) compared to the UK Medical Equipment industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is 0A7L's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A7L PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ratio4.7x

Price-To-Sales vs Fair Ratio: 0A7L is expensive based on its Price-To-Sales Ratio (8.1x) compared to the estimated Fair Price-To-Sales Ratio (4.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A7L forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$166.00
US$159.83
-3.71%
10.80%US$190.00US$130.00n/a12
Jul ’26US$152.09
US$145.92
-4.06%
8.67%US$167.00US$130.00n/a12
Jun ’26US$141.75
US$140.42
-0.94%
8.17%US$167.00US$127.00n/a12
May ’26US$107.10
US$130.92
+22.24%
8.84%US$152.00US$104.00n/a12
Apr ’26US$105.44
US$133.00
+26.14%
8.78%US$152.00US$104.00n/a12
Mar ’26US$107.19
US$133.00
+24.08%
8.78%US$152.00US$104.00n/a12
Feb ’26US$108.90
US$110.67
+1.62%
16.28%US$152.00US$86.00n/a12
Jan ’26US$88.72
US$105.58
+19.01%
15.73%US$152.00US$86.00n/a12
Dec ’25US$86.23
US$98.27
+13.97%
14.42%US$125.00US$79.00n/a11
Nov ’25US$77.00
US$98.27
+27.63%
14.42%US$125.00US$79.00n/a11
Oct ’25US$70.48
US$119.80
+69.98%
10.47%US$145.00US$100.00n/a10
Sep ’25US$72.00
US$117.55
+63.26%
9.33%US$145.00US$100.00n/a11
Aug ’25US$84.87
US$132.64
+56.28%
9.32%US$165.00US$115.00US$166.0011
Jul ’25US$108.03
US$135.45
+25.39%
8.87%US$165.00US$115.00US$152.0911
Jun ’25US$88.25
US$137.50
+55.81%
7.73%US$165.00US$122.00US$141.7510
May ’25US$109.24
US$138.50
+26.79%
6.84%US$165.00US$132.00US$107.1010
Apr ’25US$117.22
US$138.50
+18.15%
6.84%US$165.00US$132.00US$105.4410
Mar ’25US$120.87
US$138.50
+14.59%
6.84%US$165.00US$132.00US$107.1910
Feb ’25US$123.37
US$130.70
+5.94%
11.06%US$165.00US$110.00US$108.9010
Jan ’25US$107.38
US$126.70
+17.99%
11.75%US$165.00US$108.00US$88.7210
Dec ’24US$88.81
US$113.30
+27.58%
20.36%US$165.00US$85.00US$86.2310
Nov ’24US$78.52
US$129.30
+64.67%
17.39%US$165.00US$100.00US$77.0010
Oct ’24US$96.18
US$138.60
+44.10%
11.08%US$165.00US$115.00US$70.4810
Sep ’24US$107.30
US$138.60
+29.18%
11.08%US$165.00US$115.00US$72.0010
Aug ’24US$102.88
US$141.80
+37.83%
9.23%US$155.00US$115.00US$84.8710
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
US$160.83
Fair Value
3.2% overvalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/01 04:43
End of Day Share Price 2025/08/01 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

iRhythm Technologies, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PolarkBaird
David RescottBaird
Joanne WuenschBMO Capital Markets Equity Research